These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 19439805)

  • 1. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
    McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
    J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
    McPate MJ; Duncan RS; Milnes JT; Witchel HJ; Hancox JC
    Biochem Biophys Res Commun; 2005 Aug; 334(2):441-9. PubMed ID: 16011830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.
    Cordeiro JM; Brugada R; Wu YS; Hong K; Dumaine R
    Cardiovasc Res; 2005 Aug; 67(3):498-509. PubMed ID: 16039272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
    El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
    PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
    Du C; Zhang H; Harmer SC; Hancox JC
    Biochem Biophys Res Commun; 2022 Mar; 596():49-55. PubMed ID: 35114584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.
    McPate MJ; Duncan RS; Hancox JC; Witchel HJ
    Br J Pharmacol; 2008 Nov; 155(6):957-66. PubMed ID: 18724381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential.
    Hancox JC; Levi AJ; Witchel HJ
    Pflugers Arch; 1998 Nov; 436(6):843-53. PubMed ID: 9799397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome.
    Adeniran I; McPate MJ; Witchel HJ; Hancox JC; Zhang H
    PLoS Comput Biol; 2011 Dec; 7(12):e1002313. PubMed ID: 22194679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
    Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
    Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.
    McPate MJ; Duncan RS; Witchel HJ; Hancox JC
    J Mol Cell Cardiol; 2006 Sep; 41(3):563-6. PubMed ID: 16842817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of premature stimulation on HERG K(+) channels.
    Lu Y; Mahaut-Smith MP; Varghese A; Huang CL; Kemp PR; Vandenberg JI
    J Physiol; 2001 Dec; 537(Pt 3):843-51. PubMed ID: 11744759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation.
    Hancox JC; Witchel HJ; Varghese A
    Biochem Biophys Res Commun; 1998 Dec; 253(3):719-24. PubMed ID: 9918793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action potential clamp and mefloquine sensitivity of recombinant 'I KS' channels incorporating the V307L KCNQ1 mutation.
    El Harchi A; McPate MJ; Zhang YH; Zhang H; Hancox JC
    J Physiol Pharmacol; 2010 Apr; 61(2):123-31. PubMed ID: 20436212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
    Yasuda C; Yasuda S; Yamashita H; Okada J; Hisada T; Sugiura S
    J Physiol Pharmacol; 2015 Aug; 66(4):599-607. PubMed ID: 26348084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
    Luo C; Wang K; Zhang H
    PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HERG channel (dys)function revealed by dynamic action potential clamp technique.
    Berecki G; Zegers JG; Verkerk AO; Bhuiyan ZA; de Jonge B; Veldkamp MW; Wilders R; van Ginneken AC
    Biophys J; 2005 Jan; 88(1):566-78. PubMed ID: 15475579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The S140G KCNQ1 atrial fibrillation mutation affects 'I(KS)' profile during both atrial and ventricular action potentials.
    El Harchi A; Zhang H; Hancox JC
    J Physiol Pharmacol; 2010 Dec; 61(6):759-64. PubMed ID: 21224508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Channel sialic acids limit hERG channel activity during the ventricular action potential.
    Norring SA; Ednie AR; Schwetz TA; Du D; Yang H; Bennett ES
    FASEB J; 2013 Feb; 27(2):622-31. PubMed ID: 23139156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency.
    Paulussen AD; Raes A; Jongbloed RJ; Gilissen RA; Wilde AA; Snyders DJ; Smeets HJ; Aerssens J
    Cardiovasc Res; 2005 Aug; 67(3):467-75. PubMed ID: 15958262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
    Duncan RS; McPate MJ; Ridley JM; Gao Z; James AF; Leishman DJ; Leaney JL; Witchel HJ; Hancox JC
    Biochem Pharmacol; 2007 Aug; 74(3):425-37. PubMed ID: 17560554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.